Other equities analysts also recently issued research reports about the company. Commerzbank set a €25.00 ($29.07) price objective on Rhoen Klinikum and gave the company a neutral rating in a research note on Thursday, August 2nd. Berenberg Bank set a €27.75 ($32.27) target price on Rhoen Klinikum and gave the stock a neutral rating in a research report on Monday, August 6th. Independent Research set a €26.00 ($30.23) target price on Rhoen Klinikum and gave the stock a neutral rating in a research report on Wednesday, August 8th. Credit Suisse Group set a €19.00 ($22.09) target price on Rhoen Klinikum and gave the stock a sell rating in a research report on Monday, August 6th. Finally, Kepler Capital Markets set a €22.00 ($25.58) price target on shares of Rhoen Klinikum and gave the stock a sell rating in a report on Thursday, August 2nd. Five analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. Rhoen Klinikum presently has a consensus rating of Sell and a consensus price target of €22.09 ($25.68).
Rhoen Klinikum stock traded down €0.04 ($0.05) during trading on Monday, hitting €22.10 ($25.70). The stock had a trading volume of 111,500 shares, compared to its average volume of 43,281. Rhoen Klinikum has a 1 year low of €25.08 ($29.16) and a 1 year high of €32.12 ($37.35).
Rhoen Klinikum Company Profile
RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services primarily in the areas of cardiovascular, neurological disorders, oncology, pneumology, orthopedic, accident, and surgeries; rehabilitation and nursing services to the elderly; and thoracic, tumors, and psychosomatic, as well as spinal, column, and joints diseases.
See Also: Why is the conference call important?
Receive News & Ratings for Rhoen Klinikum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhoen Klinikum and related companies with MarketBeat.com's FREE daily email newsletter.